839713-36-9

Basic information

• Product Name: 1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
• Synonyms: 1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea;Urea, N-[3-(4-broMo-1-Methyl-1H-pyrazol-5-yl)-4-Methoxyphenyl]-N'-(2,4-difluorophenyl)-;Nelotanserin;1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
• CAS NO: 839713-36-9
• Molecular Formula: C₁₈H₁₅BrF₂N₄O₂
• Molecular Weight: 437.24
• Mol File: 839713-36-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 425.886 °C at 760 mmHg
• Flash Point: 211.369 °C
• Appearance: /
• Density: 1.55 g/cm³
• PKA: 12.29±0.70(Predicted)
• CAS DataBase Reference: 1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea(839713-36-9)
• EPA Substance Registry System: 1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea(839713-36-9)

Safety Data

• Hazardous Substances Data: 839713-36-9(Hazardous Substances Data)

Usage

Description

1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea is a complex organic compound with a unique molecular structure. It is characterized by the presence of a urea group, a pyrazol ring, and a methoxyphenyl group, as well as a difluorophenyl group. 1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea exhibits a wide range of biological activities and has potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea is used as a potent selective 5-HT2A inverse agonist for the treatment of various neurological and psychiatric disorders. Its low nanomolar potency on the 5-HT2A receptor, along with its high selectivity compared to other 5-HT receptors, makes it a promising candidate for the development of new therapeutic agents.
Used in Drug Discovery and Development:
1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea serves as a valuable chemical probe in drug discovery and development. Its unique structure and biological activity can be used to identify new targets and pathways involved in various diseases, as well as to develop novel therapeutic agents with improved efficacy and safety profiles.
Used in Chemical Research:
1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea is also used in chemical research to study the synthesis, properties, and reactivity of complex organic molecules. Its unique structure provides opportunities for exploring new synthetic routes, understanding the relationship between structure and biological activity, and developing new methodologies for the preparation of related compounds.

Upstream product

• 720702-45-4 3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenylamine 
• 839713-95-0 4-methoxy-3-(2-methyl-2H-pyrazol-3-yl)phenylamine 
• 59025-55-7 2,4-diflurophenylisocyanate 
• 839714-89-5 N-[4-methoxy-3-(2-methyl-2H-pyrazol-3-yl)phenyl]-acetamide 

Relevant articles and documents

COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improv

Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2, 4-difluorophenyl)urea (Nelotanserin) and Related 5-Hydroxytryptamine 2A Inverse Agonists for the Treatment of Insomnia

Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily address sleep onset latency. Through the 5-hydroxytryptamine2A (5-HT2A) receptor, serotonin (5-HT) plays a role in the regulation of sleep architecture, and antagonists/ inverse-agonists of 5-HT2A have been shown to enhance slow wave sleep (SWS). We describe here a series of 5-HT2A inverse-agonists that when dosed in rats, both consolidate the stages of NREM sleep, resulting in fewer awakenings, and increase a physiological measure of sleep intensity. These studies resulted in the discovery of 1-[3-(4-bromo-2- methyl-2i/-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin), a potent inverse-agonist of 5-HT2A that was advanced into clinical trials for the treatment of insomnia.

PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N’-[3-(1H-PYRAZOL-5-YL) PHENYL] UREAS AND INTERMEDIATES THEREOF

The present invention is directed to processes for the preparation of substituted phenylpyrazole ureas of Formula (I), that are useful as 5-HT2A serotonin receptor modulators for the treatment of disease.